Semaglutide (Ozempic/Wegovy) is an FDA-approved GLP-1 receptor agonist with robust Phase III evidence for type 2 diabetes and obesity. Retatrutide (LY3437943) is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — Phase II data (NEJM, 2023) reported approximately 24% weight reduction at 48 weeks, substantially exceeding semaglutide's ~15% in STEP trials. Retatrutide remains in Phase III development as of 2026.
Research reference only — all information on this page summarises peer-reviewed scientific literature and does not constitute medical advice. View full compound profiles: Semaglutide · Retatrutide
Mechanism Comparison
Semaglutide is a fatty-acid-modified GLP-1 analogue with ~94% homology to native GLP-1 that selectively activates GLP-1 receptors on pancreatic beta cells and hypothalamic nuclei, stimulating glucose-dependent insulin secretion, suppressing appetite, and slowing gastric emptying. Its ~7-day half-life enables once-weekly dosing. Retatrutide (LY3437943) co-activates three receptors simultaneously: GLP-1R, GIP receptor (GIPR), and glucagon receptor (GCGR). GIPR activation contributes additional energy expenditure and adipose tissue reduction; GCGR activation increases hepatic thermogenesis and energy expenditure (counterbalanced by GLP-1R/GIPR insulin-augmenting effects at therapeutic doses). This triple mechanism theoretically enables greater weight reduction than single- or dual-agonist approaches by engaging non-redundant energy homeostasis pathways.
Side-by-Side Attributes
| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Receptor targets | GLP-1R (selective) | GLP-1R + GIPR + GCGR (triple agonist) |
| Drug class | GLP-1 receptor agonist | Triagonist / triple incretin receptor agonist |
| FDA approval status | Approved — T2D (Ozempic 2017), obesity (Wegovy 2021) | Investigational — Phase III ongoing (2026) |
| Weight reduction (clinical) | ~15% (STEP 1, 68 weeks, 2.4 mg/week) | ~24% (Phase II, 48 weeks, 12 mg/week) |
| Cardiovascular outcome data | SELECT trial: 20% MACE reduction (NEJM 2023) | Phase III CVOT ongoing (2026) |
| Glycaemic control | HbA1c reduction ~2.0% (T2D trials) | HbA1c reduction ~2.2% (Phase II, diabetic cohort) |
| Administration | Subcutaneous injection (weekly); oral (Rybelsus for T2D) | Subcutaneous injection (weekly) |
| Common adverse effects | Nausea, vomiting, diarrhoea, constipation | Nausea, vomiting, diarrhoea — higher incidence at Phase II doses |
| Commercial availability | Available (Ozempic, Wegovy, Rybelsus) | Not commercially available — investigational |
| WADA status | Not prohibited | Not prohibited |
Key Research Points
- 1Semaglutide is the current clinical gold standard for GLP-1-based obesity pharmacotherapy, backed by the STEP trial programme (~15% mean weight loss, 68 weeks) and the SELECT cardiovascular outcomes trial (20% MACE reduction vs placebo, NEJM 2023). These represent the most robust outcome data available for any approved obesity pharmacotherapy.
- 2Retatrutide's Phase II data (Jastreboff et al., NEJM 2023) reported ~24.2% mean weight loss at 48 weeks at the 12 mg/week dose in non-diabetic obese participants — substantially exceeding semaglutide's STEP 1 results at comparable or longer durations. However, Phase II results frequently show larger effects than Phase III pivotal trials; retatrutide's Phase III programme was ongoing as of 2026.
- 3The mechanistic distinction is clinically meaningful: semaglutide acts through a single receptor pathway, while retatrutide's triple agonism engages GIPR and GCGR in addition to GLP-1R. The glucagon receptor component increases energy expenditure through thermogenic mechanisms, contributing to fat mass reduction independent of appetite suppression alone.
- 4Direct head-to-head data between semaglutide and retatrutide in an adequately powered randomised trial were not available as of 2026. The ~24% vs ~15% weight reduction comparison must be interpreted cautiously: the trials differ in duration, population, primary endpoints, and design.
- 5Semaglutide has an oral formulation (Rybelsus) for T2D and >5 years of post-marketing pharmacovigilance data. Retatrutide has only been studied as subcutaneous injection in published trials, and its long-term safety profile beyond Phase II follow-up remains under study.
Frequently Asked Questions
How does retatrutide differ from semaglutide?
Semaglutide is a selective GLP-1 receptor agonist — it activates GLP-1R to suppress appetite, slow gastric emptying, and augment insulin secretion. Retatrutide (LY3437943) is a triple receptor agonist that simultaneously activates GLP-1R, GIP receptors (GIPR), and glucagon receptors (GCGR). GIPR activation contributes additional adipose tissue reduction and energy expenditure; GCGR activation increases hepatic thermogenesis. Phase II data for retatrutide reported ~24% weight loss at 48 weeks versus ~15% for semaglutide in STEP 1 at 68 weeks, suggesting superior weight-reduction potential from the triple mechanism — though head-to-head Phase III comparative data are not yet available.
Is retatrutide FDA approved?
As of 2026, retatrutide (LY3437943, developed by Eli Lilly) remains investigational in Phase III clinical development and has not received FDA approval for any indication. Semaglutide is FDA-approved as Ozempic (subcutaneous, for type 2 diabetes, 2017), Wegovy (subcutaneous, for chronic weight management, 2021), and Rybelsus (oral, for T2D). Researchers should track the FDA retatrutide NDA timeline and Phase III results for updated regulatory status.
Which shows more weight loss — semaglutide or retatrutide?
Phase II data for retatrutide (Jastreboff et al., NEJM 2023) reported approximately 24% mean body weight reduction at 48 weeks at the 12 mg/week dose. The semaglutide STEP 1 trial (Wilding et al., NEJM 2021) reported approximately 14.9% mean weight loss at 68 weeks with 2.4 mg/week. The retatrutide Phase II data suggest greater weight reduction attributable to its triple-receptor mechanism. However, these are different trials with different durations and designs — a direct head-to-head comparison in a single randomised trial is required for a definitive efficacy ranking.
Deep Dive
For extended mechanism analysis, trial data, and regulatory context, see the full research article:
Retatrutide: Triple Receptor Agonist Research and Phase III Overview →Full compound profile
Semaglutide
Full compound profile
Retatrutide